NR3C1 and melanoma: The most consistent candidate drug treatments for invasive melanoma were glucocorticoid receptor (NR3C1) agonists, AXL inhibitors, PARP1 inhibitors and HDAC inhibitors, as target gene expression for drug families predicted to target invasive melanoma.